At the 129th Anniversary Ceremony of Shanghai Jiao Tong University (SJTU), the School of Medicine proudly celebrates three individuals and one team who have been honored with the 2025SJTU President’s Award. The recipientsare Dr. Shen Baiyong, Vice President ofRuijin Hospital; Dr. Lin Haodong, Administrative Director of theTrauma Clinical Medicine Center atShanghai General Hospital; Hu Jiateng, a PhD candidate in Vascular Surgery (Class of 2023); The Cardiovascular Innovation Team at Renji Hospital.
In addition, Professor Wang Weiqing, Director of Endocrinology and Metabolism at Ruijin Hospital, was named the recipient of the Third“Ruiyuan Science and Technology Prize”.
2025 SJTU President’s Award
Shen Baiyong
Dr. Shen is the Vice President of Ruijin Hospital, Director of the Pancreatic Disease Center, Professor, Chief Physician, and Doctoral Supervisor. A leading figure in pancreatic cancer research and treatment for over 30 years, he has authored 185 high-impact papers in the past five years alone—published in top journals such asNature Medicine, JAMA Surgery, andAnnals of Surgery—with a cumulative impact factor of 1,122. His work earned him numerous honors, including theNational Science and Technology Progress Award and Foreign Corresponding Member of the French National Academy of Medicine. His patented innovations have generated over 150 million yuan through commercialization
Lin Haodong
Dr. Lin is administrative director of the Trauma Clinical Medicine Center at Shanghai General Hospital and obtained the 2023Shanghai Youth Outstanding Science and Technology Contribution Award. He has long championed the rehabilitation of individuals with disabilities, revolutionizing surgical techniques to restore urinary, defecatory, and motor functions in patients with spinal cord injuries. As a medical advisor for China’s“Spinal Injury Rehabilitation Hotline” and one of the country's outstanding young talents in the field, he has improved patients’ quality of life and facilitated their reintegration into society.
Hu Jiateng
Hu is a second-year PhD student in Surgery at SJTUSM. He pioneered a patented minimally invasive laser fenestration system for treating aortic diseases. As a Party representative and student ambassador, he actively advocates for youth. A recipient of the national scholarship and over 50 honors, including national innovation awards, Hu diagnosed and treated Yunnan’s first known case of Parkes-Weber Syndrome and founded China’s first public education center for peripheral vascular disease. Widely recognized by national media, he brings to life the boundless spirit of medicine.
The Cardiovascular Innovation Team at Renji Hospital
Driven by the mission of clinical problem-solving, this team addresses major national needs in cardiovascular disease prevention and treatment. They have nurtured a generation of top-tier talents including recipients of the National Science Fund for Distinguished Young Scholars and Yangtze River Scholars. The team has led nearly 100 national-level research projects, including key initiatives from the Ministry of Science and Technology, and major project of Science and Technology Innovation 2030 of the National Health Commission. Their work is featured in international cardiology textbooks, WHO health action plans, and over 10 global clinical guidelines. In 2024, they were awarded theNSFC Innovative Research Group distinction.
The President’s Award is the highest spiritual honor at SJTU, recognizing faculty, staff, and students who embody the university’s core values, patriotic dedication, and excellence in service and innovation.
2025 Ruiyuan Science and Technology Prize
Wang Weiqing
Wang is the Director of Department of Endocrinology and Metabolism, Ruijin Hospital and a member of Academic Advisory Committee, Chinese Academy of Medical Sciences. With over 40 years of experience, Wang is a leading figure in the field of endocrine and metabolic diseases. She has pioneered a new model of diagnosis and treatment that emphasizes precision, translational research, and scalability.
She has led four major national clinical studies:
① BPROAD Study: Demonstrated a 21% reduction in cardiovascular events with lower systolic BP (<120 mm Hg); presented at the AHA Centennial and published in NEJM.
② 4C Cohort: Identified key modifiable factors in cardiovascular, cancer, and all-cause mortality, and confirmed obesity with insulin resistance as a primary driver of diabetes in Chinese populations.
③ GOCY Study: Revealed the role of gut microbiota (e.g., Akkermansia) in obesity and glucose control among adolescents.
④ National Metabolic Management Center (MMC) Program: Built a national network managing 3 million diabetic patients across 2,000 hospitals in 32 provinces and cities, doubling glycemic control rates from 22% to 53%—the largest diabetes care program globally.
She also established the“Ruijin Metabolic Biobank” and launched the ChinaMAPmulti-omics project. His research revealed a novel brain-gut axis for fat absorption and identified kudzu extract as a potential treatment, opening a new frontier in weight loss. He has contributed 39 diagnostic technologies, 22 clinical guidelines, and 10 national pathways, and leads China’s only CAP-certified endocrine lab.
The Ruiyuan Science and Technology Prize was established in February 2022 through a donation by SJTU Board Member Chen Guangming. It honors bold, trailblazing researchers who achieve original breakthroughs in basic science or address major national strategic needs. It is awarded annually in five categories: Mathematical and Physical Sciences, Engineering and Materials, Information and Space, Marine Science, and Life and Medical Sciences.
